ArticleDiscover oncology2025

Tislelizumab plus anlotinib with or without radiotherapy as first-line therapy in advanced hepatocellular carcinoma: a single center, non-randomized retrospective case-control study.

Guishu Wu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.